Haven Barton, RN
Curriculum Vitae
1500 N. Dixie Highway
Suite 305
West Palm Beach FL 33401
561-655-9055
hbarton@beerdermatology.com

Education

ASN - Nursing
Palm Beach State College- RN (December 2021)
Lake Worth, FL 33461

AA – Pre-Nursing (2014-2016)
Tallahassee Community College, Tallahassee, FL 32304

Work Experience

3/28/22 – Present **Research Coordinator – Research Institute of the Southeast, LLC (Dr. Kenneth Beer)**

5/24/21 – 8/2/21 **File Clerk – King Ranch Inc.**
Accounts Receivable, Corresponding with Customers and Businesses, File Organization, Statement Preparation, Customer Service, Microsoft Office Background, Excel

5/18/20 – 3/15/21 **Sales Associate – La Casa Hermosa**
Billing, Customer Service, Event Coordinator, Computer Program Skills, Excel

2014-2016 – **Childcare Assistant – Wee Care Day Care Center**
Time Management, Child Care, Care Coordinator, Lesson Plan preparation

Credentials

Board Examination, Registered Nurse, 2023

HavenBarton
3/15/2024

March 15, 2024

Honors and Awards
2016 **Dean's List** (Tallahassee Community College)
2015 **President's List** (Tallahassee Community College)

Accreditations
BCLS American Heart Association

Certificates
03/28/22 **CITI**
03/29/22 **IATA Mayo Clinic**

Clinical Trials:

Phase II

Research Coordinator with Research Institute of the Southeast – Caliway Biopharmaceuticals Co., Ltd. – Protocol CBL-0205: A Phase 2b, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection Compared with CBL-A1 and CBL-A2 for Reducing Abdominal Subcutaneous Fat.
Research Coordinator with Research Institute of the Southeast – Bausch Health/Valeant -Protocol V01-126A-202: IDP -126 - Phase 2, Multicenter, Randomized, Double Blind, Vehicle-Controlled, Clinical study to compare the Safety and Efficacy of IDP-126 Gel to Epiduo Forte Ge l(0.3% adapalene/2.5% BPO), in the treatment of Acne Vulgaris.

Research Coordinator with Research Institute of the Southeast - Onabota-X Protocol 2042-201-008: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines

Research Coordinator with Research Institute of the Southeast - Protocol ET-01-LCL-210: A multicenter, Randomized, Double-Blind, vehicle-controlled, two-armed, parallel dose group, to evaluate the safety and efficacy of ET-01 botulinum toxin in skin pre-conditioning to help the drug penetrate.

Phase III

Research Coordinator with Research Institute of the Southeast - (Phase 3b) Protocol Number: J2T-MC-KGBO An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab.

Research Coordinator with Research Institute of the Southeast - Phase 3 Protocol 2029-701-008 Transverse Neck Lines - Multicenter, Evaluator-blinded, Randomized, Controlled Study of the Safety and Effectiveness of JUVEDERM VOLITE XC Injectable Gel for Improvement in the Neck Appearance.

Research Coordinator with Research Institute of the Southeast - Phase 3 Protocol M21-309: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence

Research Coordinator with Research Institute of the Southeast Phase 3 Protocol M21-323: A Phase 3 Multicenter, Open-labeled Extension Study to Evaluate the Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence

Phase IV

Research Coordinator with Research Institute of the Southeast- Protocol M930521003 - Prospective, multicenter, controlled, evaluator-blind, randomized study to investigate the effectiveness and safety of diluted RADIESSE® for treatment of décolleté wrinkles.

Pivotal Studies

Research Coordinator with Research Institute of the Southeast- Protocol 43N3US2204 (Pivotal) - A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0116 for correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds.